Poxel’s PXL770 and PXL065 Receives Orphan Drug Designation from the EC to Treat Adrenoleukodystrophy
Shots:
- The decision is followed by a positive COMP opinion. PXL770 and PXL065 also received ODD and FTD from the US FDA for same indication. The P-II PoC biomarker studies are to be initiated in ALD patients with adrenomyeloneuropathy
- PXL065 also evaluated in P-II study (DESTINY-1) for the treatment of NASH and met its 1EPs. Along with ALD, PXL770 is also focused on the treatment of autosomal dominant polycystic kidney disease
- PXL770, AMPK activator and PXL065, deuterium-stabilized R-stereoisomer of pioglitazone which shows effects via multiple non-genomic pathways engaged by thiazolidinedione molecule
Ref: Businesswire | Image: Poxel
Related News:- CardioRenal Systems’ RenalGuard Therapy Device Receives the US FDA’s Breakthrough Device Designation for Cardiac Surgery Associated AKI
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
